22nd Biennial Course in Urologic Oncology

Course Overview

Beginning in 1982, the multidisciplinary Urologic Cancer Course was designed as a biennial course bringing together expertise from all the Harvard teaching hospitals in conjunction with invited, world-class experts in urologic oncology, medical oncology, and radiation oncology. Dr. Marc B. Garnick led the course from 1982 to 1996 at which time Dr. Jerome P. Richie assumed the leadership until 2014. Dr. Phillip W. Kantoff then led the course and subsequently in 2016 Dr. Adam Kibel, Dr. Toni Choueiri, and Dr. Anthony V D’Amico co-led the course.

Who Should Attend

• Physician Assistants
• Nurse Practitioners
• Primary Care Physicians
• Specialty Physicians
• Nurses
• Residents and Fellows
• Other

Learning Objectives

Upon completion of this activity, participants will be able to:

• Demonstrate the optimal management of oligometastatic prostate, bladder, and renal cancer.
• Explain the role of immunotherapy in the management of bladder, prostate, and renal cancer.
• Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for observation, active surveillance, or other definitive management approaches.
• Apply Level 1 evidence on the use of novel treatment paradigms and updated surveillance options for patients with prostate, renal, bladder, penile, or testicular cancer.
• Apply novel minimally invasive treatments for GU malignancies including prostate, bladder, and kidney cancer.
• Use multiparametric MRI, fusion biopsy, and novel markers in men at risk for prostate cancer.